CRISPR THERAPEUTICS AG (CRSP) Operating cash flow 2016–2025
CRISPR THERAPEUTICS AG (CRSP) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$345.0MFY2025 · since FY2016: -$52.9M → -$345.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$345.0M | -141.7% |
| FY2024 | -$142.8M | +45.2% |
| FY2023 | -$260.4M | +47.5% |
| FY2022 | -$495.7M | -192.0% |
| FY2021 | $539.0M | +326.1% |
| FY2020 | -$238.4M | -520.6% |
| FY2019 | $56.7M | +158.9% |
| FY2018 | -$96.2M | -37.3% |
| FY2017 | -$70.1M | -32.6% |
| FY2016 | -$52.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net incomeCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating incomeCRSP Operating marginCRSP Free cash flowCRSP Capital expendituresCRSP Return on equityCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Total liabilitiesCRSP Shareholders’ equityCRSP overview →